AngioDynamics (ANGO) vs. Teleflex (TFX) Financial Analysis

Teleflex (NYSE: TFX) and AngioDynamics (NASDAQ:ANGO) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, dividends, earnings and risk.

Valuation and Earnings

This table compares Teleflex and AngioDynamics’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Teleflex $1.99 billion 4.77 $521.06 million $5.23 40.28
AngioDynamics $349.64 million 1.79 $51.23 million $0.19 90.00

Teleflex has higher revenue and earnings than AngioDynamics. Teleflex is trading at a lower price-to-earnings ratio than AngioDynamics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Teleflex has a beta of 1.05, indicating that its stock price is 5% more volatile than the S&P 500. Comparatively, AngioDynamics has a beta of 1.15, indicating that its stock price is 15% more volatile than the S&P 500.


Teleflex pays an annual dividend of $1.36 per share and has a dividend yield of 0.6%. AngioDynamics does not pay a dividend. Teleflex pays out 26.0% of its earnings in the form of a dividend.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Teleflex and AngioDynamics, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Teleflex 0 1 5 0 2.83
AngioDynamics 0 2 3 0 2.60

Teleflex currently has a consensus price target of $228.00, indicating a potential upside of 8.23%. AngioDynamics has a consensus price target of $18.40, indicating a potential upside of 7.60%. Given Teleflex’s stronger consensus rating and higher probable upside, equities analysts clearly believe Teleflex is more favorable than AngioDynamics.


This table compares Teleflex and AngioDynamics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Teleflex 12.36% 16.12% 7.78%
AngioDynamics 2.00% 5.19% 3.79%

Insider & Institutional Ownership

92.6% of Teleflex shares are held by institutional investors. Comparatively, 89.2% of AngioDynamics shares are held by institutional investors. 2.4% of Teleflex shares are held by company insiders. Comparatively, 1.9% of AngioDynamics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.


Teleflex beats AngioDynamics on 14 of the 16 factors compared between the two stocks.

Teleflex Company Profile

Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM). The Company’s products include oxygen therapy products, aerosol therapy products, spirometry products, and ventilation management products, which are offered under Hudson RCI brand. As of December 31, 2016, it manufactured its products at approximately 30 manufacturing sites, with manufacturing operations located in the Czech Republic, Germany, Malaysia, Mexico and the United States. Its all others businesses include single-use respiratory, urology and cardiac care products, as well as capital equipment.

AngioDynamics Company Profile

AngioDynamics, Inc. designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures. The Company offers products within three product groupings: Peripheral Vascular, Vascular Access and Oncology/Surgery. The Company’s Peripheral Vascular products include Fluid Management, Venous, Thrombus Management, as well as other core products. The Company’s BioFlo products incorporate Endexo Technology into the manufacturing and design of its Vascular Access products. Its Oncology/Surgery product offerings include its Microwave Ablation products, Radiofrequency Ablation (RFA) and its NanoKnife product lines.

What are top analysts saying about Teleflex Incorporated? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Teleflex Incorporated and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit